CTMX - CytomX Therapeutics Inc Stock Price, Fair Value and News

$1.09-0.01 (-0.91%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CTMX Price Action

Last 7 days

-1.8%

Last 30 days

25.3%

Last 90 days

-8.4%

Trailing 12 Months

-22.7%

CTMX RSI Chart

CTMX Valuation

Market Cap

85.3M

Price/Earnings (Trailing)

6.17

Price/Sales (Trailing)

0.67

EV/EBITDA

2.97

Price/Free Cashflow

-0.96

CTMX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CTMX Fundamentals

CTMX Revenue

Revenue (TTM)

126.6M

Rev. Growth (Yr)

26.71%

Rev. Growth (Qtr)

33.12%

CTMX Earnings

Earnings (TTM)

13.8M

Earnings Growth (Yr)

91.71%

Earnings Growth (Qtr)

187.79%

CTMX Profitability

EBT Margin

11.89%

Return on Equity

-58.97%

Return on Assets

9.95%

Free Cashflow Yield

-104.08%

CTMX Investor Care

Shares Dilution (1Y)

16.82%

CTMX Alerts

JANUS HENDERSON GROUP PLC reported owning 6.2% of CTMX [2024-11-14]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	119.2M	119.6M	126.6M	0
2023	67.6M	79.5M	94.7M	101.2M
2022	38.2M	42.2M	44.2M	53.2M
2021	29.7M	31.5M	33.3M	37.3M
2020	74.9M	72.9M	69.6M	68.4M
2019	74.8M	62.5M	60.7M	57.5M
2018	74.2M	86.7M	75.1M	59.5M
2017	24.5M	30.1M	50.8M	71.6M
2016	8.2M	9.2M	10.8M	15.0M
2015	6.2M	7.6M	7.6M	7.7M
2014	1.9M	3.0M	4.0M	5.1M
2013	0	0	0	888.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, Astellas Pharma Inc., ModernaTX, Inc., and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in South San Francisco, California.

CEO	Dr. Sean A. McCarthy D.Phil., DPHIL
WEBSITE	cytomx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	116

CytomX Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for CytomX Therapeutics Inc? What does CTMX stand for in stocks?

CTMX is the stock ticker symbol of CytomX Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CytomX Therapeutics Inc (CTMX)?

As of Fri Dec 20 2024, market cap of CytomX Therapeutics Inc is 85.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTMX stock?

You can check CTMX's fair value in chart for subscribers.

Is CytomX Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CTMX is over valued or under valued. Whether CytomX Therapeutics Inc is cheap or expensive depends on the assumptions which impact CytomX Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTMX.

What is CytomX Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, CTMX's PE ratio (Price to Earnings) is 6.17 and Price to Sales (PS) ratio is 0.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTMX PE ratio will change depending on the future growth rate expectations of investors.